Atul Katyal, MD
Nephrology · White Plains, MDNPI 1245270735
Payments from drug & device makers
Across 83 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$299
- Otsuka America Pharmaceutical, Inc.$250
- Akebia Therapeutics Inc$145
- Vifor Pharma, Inc.$142
- OPKO Pharmaceuticals, LLC$133
- Ardelyx, Inc.$119
- plus $698 from 15 others
What the payments were for
- Food & beverage$1,66493%
- Education$1237%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $299 |
| Otsuka America Pharmaceutical, Inc. | 9 | $250 |
| Akebia Therapeutics Inc | 8 | $145 |
| Vifor Pharma, Inc. | 7 | $142 |
| OPKO Pharmaceuticals, LLC | 7 | $133 |
| Ardelyx, Inc. | 5 | $119 |
| Fresenius USA Marketing, Inc. | 6 | $112 |
| Novartis | 4 | $86 |
| Baxter Healthcare | 1 | $66 |
| Bayer | 3 | $60 |
| Calliditas Therapeutics US Inc. | 2 | $57 |
| Amgen | 3 | $56 |
| Travere Therapeutics, Inc. | 4 | $53 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Boehringer Ingelheim | 1 | $33 |
| Mallinckrodt Enterprises LLC | 1 | $29 |
| Qiagen, LLC | 1 | $29 |
| Novo Nordisk | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| GSK | 1 | $17 |
How this compares
$1,788 in reported general payments places this provider in the 65th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 13 | $3,278 |
| Calcitriol | 50 | $1,318 |
| Calcium Acetate | 11 | $1,266 |
| Amlodipine Besylate | 87 | $811 |
| Nifedipine ErNifedipine | 24 | $660 |
| Hydralazine Hcl | 18 | $613 |
| Atorvastatin Calcium | 13 | $326 |
| Metoprolol Succinate | 23 | $318 |
| Metoprolol Tartrate | 31 | $237 |
| Hydrochlorothiazide | 18 | $197 |
| Furosemide | 38 | $180 |
| Losartan Potassium | 22 | $172 |
| Cephalexin | 20 | $59 |
Paid to pharmacies, not to this prescriber.
Other nephrology in White Plains
- Christopher SperatiBaltimore$1.5M
- Michelle EstrellaBaltimore$1.2M
- Mohamed AttaBaltimore$1.1M
- Chirag ParikhBaltimore$1M
- Mario BelledonnePotomac$715K
- Matthew WeirBaltimore$518K
- Kiran SamindlaFrederick$491K
- Saeed KronfliTakoma Park$463K
- Duvuru GeethaBaltimore$409K
- Preeti ChandraBaltimore$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.